Zydus Pharmaceuticals
As a leading generic pharmaceutical company in the US, Zydus Pharmaceuticals offers a wide variety of FDA approved medications that may help patients treat and manage disease, fight infection, and improve overall health and wellness.
Zydus Lifesciences - Wikipedia
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, [3] is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs.
Zydus Pharmaceuticals
As one of the key players amongst pharmaceutical manufacturing companies, Zydus Lifesciences has manufacturing capabilities across the entire pharmaceutical value chain including formulations, APIs, vaccines, biosimilars, complex products, …
About Zydus Group - The Leading Indian Pharma Company
Zydus Group is the leading global pharma healthcare providers in India. We are USFDA Approved API manufacturers supply Healthcare and Wellness Pharmaceutical Products.
Zydus Pharmaceuticals
Zydus launches first AP rated generic of Methylene Blue Injection! Learn more. Access our product Medication Guides
ALS treatment: Zydus receives USFDA Orphan Drug Designation …
1 day ago · Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for treating amyotrophic lateral sclerosis (ALS), a rare fatal neurodegenerative disease. Clinical trials indicate promising results, and further trials are planned. ALS affects over 30,000 people in the US annually.
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIOTM (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg.
FDA approves Zydus' trial of Usnoflast for ALS treatment
4 days ago · The multi-centre, placebo-controlled trial aims to enrol 210 subjects with ALS. Credit: David Herraez Calzada / Shutterstock. The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor ...
Zydus announces USFDA Orphan Drug Designation for Usnoflast …
1 day ago · Zydus has also received approval from the USFDA to initiate a Phase 2(b) clinical trial for Usnoflast in ALS patients. This trial will be a randomized, double-blind, placebo-controlled study. With the Orphan Drug Designation, Zydus aims to expedite the development of Usnoflast and provide a new treatment option for ALS patients.
Zydus Pharmaceuticals (USA) Inc. Company Information - Drugs.com
Oct 20, 2023 · Zydus Pharmaceuticals (USA) Inc. manufactures, markets and/or distributes more than 242 drugs in the U.S.
- Some results have been removed